U043 - Merkel Cell Carcinoma: Diagnosis, Management and Controversies
Saturday, February 17; 4:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Utilize recent developments in the clinical management of Merkel cell carcinoma, including sentinel lymph node biopsy, adjuvant therapy, and systemic therapy, to guide multidisciplinary care of patients with MCC.
- Identify areas of consensus and controversy regarding the clinical and prognostic characteristics of MCC.
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma with a higher disease-specific mortality than melanoma. MCC is rare, but the incidence is increasing in the U.S. Clinical management is challenging due to lack of evidence-based data and wide-ranging treatment recommendations in the literature. Multidisciplinary care is frequently indicated and encouraged by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. This session will focus on current concepts in the diagnosis and management of MCC.
- Bichakjian, Christopher K., MD: no financial relationships exist with commercial interests.
- Harms, Kelly L, MD, PhD: no financial relationships exist with commercial interests.